从资金流向上来看，当日医疗美容板块主力资金净流入6532.5万元，游资资金净流出1191.11万元，散户 资金净流出5341.39万元。医疗美容板块个股资金流向见下表： 证券之星消息，12月16日医疗美容板块较上一交易日上涨0.98%，爱美客领涨。当日上证指数报收于 3824.81，下跌1.11%。深证成指报收于12914.67，下跌1.51%。医疗美容板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 300896 | 爱美客 | 140.56 | 2.02% | 4.62万 | 6.53 Z | | 688363 | 华熙生物 | 43.29 | -0.07% | 3.98万 | 1.74亿 | | 920982 | 锦波生物 | 262.15 | -0.32% | 1.66万 | 4.44 Z | | 000615 | *ST美谷 | 4.09 | -1.45% | 5.75万 | 2369.06万 | 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备31010 ...

Core Insights - The beauty care industry experienced a net inflow of funds amounting to 105 million yuan on December 16, with a sector increase of 0.66% despite the Shanghai Composite Index declining by 1.11% [1] Industry Performance - Among the sectors, beauty care ranked second in terms of growth, following retail trade and social services, which rose by 1.32% and 0.13% respectively [1] - The beauty care sector had 29 stocks, with 15 rising and 14 falling in value [1] Fund Flow Analysis - The total net inflow of funds in the beauty care sector was 105 million yuan, with 17 stocks experiencing net inflows [1] - The top three stocks with significant net inflows were: - Aimeike (爱美客) with 39.98 million yuan - Qingsong Co. (青松股份) with 20.96 million yuan - Shuiyang Co. (水羊股份) with 20.30 million yuan [1] - The stocks with the highest net outflows included: - Proya (珀莱雅) with 8.62 million yuan - Zhongshun Jierou (中顺洁柔) with 6.81 million yuan - Yanjian Co. (延江股份) with 5.90 million yuan [1] Stock Performance - Notable stock performances included: - Aimeike (爱美客) increased by 2.02% - Qingsong Co. (青松股份) increased by 1.03% - Shuiyang Co. (水羊股份) increased by 1.20% [1] - Conversely, stocks like Proya (珀莱雅) and Zhongshun Jierou (中顺洁柔) saw declines in their values [1]

Core Insights - The article highlights the launch of the Super CEO series by Zhito Finance for the ninth consecutive year, featuring various sub-lists that reflect the diverse driving forces behind China's economic growth, particularly in the healthcare sector [1] Industry Overview - The Chinese pharmaceutical manufacturing industry is experiencing a decline, with revenue of 1,227.52 billion yuan in the first half of 2025, down 1.2% year-on-year, and total profit of 176.69 billion yuan, down 2.8% year-on-year, indicating ongoing industry pressure and deepening segmentation [1] - Since 2025, numerous policies have been introduced to support high-quality development in innovative pharmaceuticals, including measures to enhance the clinical trial approval process and the introduction of a commercial insurance directory for innovative drugs [2] - The medical device export sector continues to grow, with a total import and export value of 41.09 billion USD in the first half of 2025, a 1.1% increase year-on-year, while imports decreased by 3.9%, indicating a shift towards domestic alternatives in high-end equipment [3] Investment Trends - The overseas business development (BD) orders for innovative pharmaceuticals have reached a record high, surpassing 60 billion USD, with significant transactions indicating a shift in China's role from a follower to a contributor in the global pharmaceutical landscape [4] - Capital preferences are improving, with the healthcare industry in China seeing a recovery in financing activities, particularly in medical devices and innovative pharmaceuticals, with significant investments in areas like cancer screening and AI healthcare [5] Future Outlook - The 15th Five-Year Plan emphasizes the importance of health in economic development, aiming to enhance public health and support the growth of innovative drugs and medical devices, which will shape the future of the healthcare industry in China [6] - The aging population, active policy support, and the internationalization of medical devices are driving demand and supply upgrades in the healthcare sector, presenting both opportunities and challenges for industry leaders [6] CEO Insights - The Super CEO list features 25 leaders whose companies have shown median revenue growth of 6.11% and net profit growth of 16.08%, with an average market capitalization of 86.1 billion yuan [9] - The list includes a notable representation of women leaders, with three female CEOs demonstrating strong strategic vision in high-barrier industries [10] - The majority of CEOs on the list have advanced degrees, reflecting the industry's demand for leaders with deep scientific understanding and business acumen [10] Company Highlights - Li Ge, CEO of WuXi AppTec, leads the list, showcasing strong performance with a revenue of 32.857 billion yuan in the first three quarters of 2025, a year-on-year increase of 18.61% [17] - Zhu Yi, CEO of BaiLi TianHeng, achieved significant revenue growth through strategic partnerships, emphasizing the importance of building a robust product pipeline [18] - Wu Hao, CEO of Mindray, reported a revenue of 36.726 billion yuan in 2024, with a focus on R&D and international expansion [19] - Zhong Huijuan, CEO of Hansoh Pharmaceutical, became the richest woman in China with a revenue of 12.261 billion yuan in 2024, driven by innovative drug sales [19] - Shi Yifeng, CEO of Aimeike, led the company to a revenue of 3.026 billion yuan in 2024, emphasizing shareholder value through high dividend payouts [20]

证券日报网讯 12月11日，爱美客在互动平台回答投资者提问时表示，截至2025年12月10日，公司股东 人数为60403户。 （文章来源：证券日报） ...

Group 1 - The medical beauty sector experienced a decline of 1.21% on December 11, with Ai Meike leading the drop [1] - The Shanghai Composite Index closed at 3873.32, down 0.7%, while the Shenzhen Component Index closed at 13147.39, down 1.27% [1] - A table detailing the individual stock performance within the medical beauty sector was provided [1] Group 2 - In terms of capital flow, the medical beauty sector saw a net outflow of 58.89 million yuan from main funds, while retail funds had a net inflow of 34.55 million yuan [2] - Speculative funds recorded a net inflow of 24.35 million yuan [2] - A table showing the capital flow for individual stocks in the medical beauty sector was included [2]

Core Points - The Shenzhen-Hong Kong Stock Connect Medical Index (983036) closed at 4327.65 points, down 0.28%, with a trading volume of HKD 7.682 billion and a turnover rate of 0.9% [1] - Among the index constituents, 21 stocks rose while 36 stocks fell, with Kewei Medical leading the gainers at a 4.14% increase and Xianjian Technology leading the decliners at a 9.14% decrease [1] Index Constituents Summary - The top ten constituents of the Shenzhen-Hong Kong Stock Connect Medical Index include: - Mindray Medical (sz300760) with a weight of 14.56%, latest price at HKD 198.00, and a market cap of HKD 240.063 billion, down 0.36% [1] - Yier Eye Hospital (sz300015) with a weight of 11.62%, latest price at HKD 11.23, and a market cap of HKD 104.724 billion, down 0.62% [1] - Lejin Medical (sz300003) with a weight of 4.85%, latest price at HKD 15.64, and a market cap of HKD 28.831 billion, down 0.64% [1] - Aimeike (sz300896) with a weight of 4.80%, latest price at HKD 143.25, and a market cap of HKD 43.346 billion, up 1.47% [1] - Yuyue Medical (sz002223) with a weight of 4.66%, latest price at HKD 35.68, and a market cap of HKD 35.768 billion, up 0.17% [1] - Yingke Medical (sz300677) with a weight of 3.64%, latest price at HKD 41.76, and a market cap of HKD 27.360 billion, down 0.17% [1] - Furuijia (sz300049) with a weight of 3.59%, latest price at HKD 69.33, and a market cap of HKD 18.371 billion, down 0.82% [1] - Meinian Health (sz002044) with a weight of 3.58%, latest price at HKD 5.09, and a market cap of HKD 19.924 billion, up 0.39% [1] - Sinopharm Holdings (hk01099) with a weight of 3.35%, latest price at HKD 18.15, and a market cap of HKD 56.638 billion, down 0.40% [1] - Ping An Good Doctor (hk01833) with a weight of 2.63%, latest price at HKD 12.23, and a market cap of HKD 26.434 billion, down 3.24% [1] Capital Flow Analysis - The index constituents experienced a net outflow of HKD 382 million from institutional investors, while retail investors saw a net inflow of HKD 329 million [1] - Notable individual stock capital flows include: - Meinian Health (sz002044) with a net inflow of HKD 23.6308 million from institutional investors [2] - Aimeike (sz300896) with a net inflow of HKD 5.8353 million from institutional investors [2] - Yier Eye Hospital (sz300015) with a net outflow of HKD 20.7620 million from retail investors [2]

证券日报网讯12月8日，爱美客（300896）在互动平台回答投资者提问时表示，价值创造和可持续发展 是上市公司市值管理的基石，规范透明的信披环境和良好的投资者关系是价值实现的途径。公司通过聚 焦主业，以客户需求为导向，不断技术创新、实现产品与服务升级等方式提升公司内在价值，同时也通 过国际化战略布局，优化资产配置，提升核心竞争力，推动市值的长期稳定和提升。 ...

Core Insights - The Shenzhen-Hong Kong Stock Connect Medical Index (983036) closed at 4406.89 points, down 0.24%, with a trading volume of HKD 7.939 billion and a turnover rate of 0.88% [1] - Among the index constituents, 23 stocks rose while 34 stocks fell, with Yiyang Sunshine leading the gainers at 3.98% and Jinxin Fertility leading the decliners at 3.89% [1] Index Constituents Summary - The top ten constituents of the Shenzhen-Hong Kong Stock Connect Medical Index are as follows: - Mindray Medical (sz300760) holds a weight of 14.56%, latest price at HKD 200.05, down 1.16%, with a market cap of HKD 242.549 billion [1] - Aier Eye Hospital (sz300015) has a weight of 11.62%, latest price at HKD 11.40, up 0.89%, with a market cap of HKD 106.31 billion [1] - Lepu Medical (sz300003) has a weight of 4.85%, latest price at HKD 15.89, up 0.38%, with a market cap of HKD 29.292 billion [1] - Aimeike (sz300896) has a weight of 4.80%, latest price at HKD 142.81, down 0.11%, with a market cap of HKD 43.213 billion [1] - Yuyue Medical (sz002223) has a weight of 4.66%, latest price at HKD 35.84, down 0.83%, with a market cap of HKD 35.929 billion [1] - Yingke Medical (sz300677) has a weight of 3.64%, latest price at HKD 43.72, up 0.97%, with a market cap of HKD 28.644 billion [1] - Furuide (sz300049) has a weight of 3.59%, latest price at HKD 70.75, up 0.71%, with a market cap of HKD 18.747 billion [1] - Meinian Onehealth (sz002044) has a weight of 3.58%, latest price at HKD 5.13, down 0.58%, with a market cap of HKD 20.08 billion [1] - Sinopharm (hk01099) has a weight of 3.35%, latest price at HKD 18.51, down 0.97%, with a market cap of HKD 57.767 billion [1] - Ping An Good Doctor (hk01833) has a weight of 2.63%, latest price at HKD 13.18, up 0.21%, with a market cap of HKD 28.495 billion [1] Capital Flow Analysis - The index constituents experienced a net outflow of main funds totaling HKD 230 million, while retail investors saw a net inflow of HKD 268 million [1] - Detailed capital flow for specific stocks shows: - Furuide (sz300049) had a main fund net inflow of HKD 8.7323 million, with retail outflows of HKD 3.3726 million [2] - Aier Eye Hospital (sz300015) had a main fund net inflow of HKD 6.6536 million, with retail outflows of HKD 1.8752 million [2] - Lepu Medical (sz300003) had a main fund net inflow of HKD 3.7716 million, with retail outflows of HKD 0.7273 million [2]

Investment Rating - The report maintains a "Positive" outlook on the cosmetics and medical beauty industry, despite recent underperformance compared to the market [4][5]. Core Insights - The cosmetics and medical beauty sector has shown weaker performance, with the Shenwan Beauty Care Index declining by 2.0% from November 28 to December 5, 2025, underperforming the market [4][5]. - Douyin's performance in November met expectations, with domestic brands preparing actively for the upcoming Double 12 sales event, indicating a strong competitive landscape for domestic products [4][10]. - The report highlights the leading market share of Minoxidil products, particularly from Mandi International, which has established itself as a top brand in the hair growth sector [11][12]. Summary by Sections Industry Performance - The Shenwan Cosmetics Index fell by 2.2%, while the Shenwan Personal Care Index also dropped by 2.0%, both underperforming against the Shenwan A Index [4][5]. - The top-performing stocks in the sector included Juzhibio (+5.9%) and Hongmian Co. (+3.5%), while the worst performers were Kelao Co. (-7.6%) and Baiya Co. (-4.8%) [6]. Key Market Developments - Mandi International has dominated the Minoxidil market, achieving a revenue growth from 982 million yuan in 2022 to approximately 1.455 billion yuan in 2024, with a CAGR of 21.7% [12][13]. - The company has maintained a leading position in the market for ten consecutive years, with a market share of about 57% in the hair loss treatment sector and 71% in the Minoxidil product market as of 2024 [12][14]. E-commerce Insights - In November 2025, Douyin's domestic brand GMV showed significant growth, with brands like Han Shu and New Page experiencing double-digit increases [15][18]. - The overall retail sales of cosmetics in October 2025 grew by 9.6%, driven by the Double 11 shopping festival, indicating a robust recovery in consumer spending [18][20]. Company Announcements - Lin Qingxuan updated its IPO prospectus for the Hong Kong market, reporting a revenue of 1.052 billion yuan in the first half of 2025, a year-on-year increase of 98.3% [22][19]. - The company plans to expand its research and development team and explore international markets in Southeast Asia [22][19]. Market Trends - The Chinese consumer healthcare market is projected to grow from 9.313 billion yuan in 2018 to 16.420 billion yuan in 2024, with a CAGR of 9.9% [13]. - The report emphasizes the increasing market share of domestic brands in the skincare sector, with a notable rise in the competitive landscape against international brands [24].

Group 1 - The core viewpoint of the article highlights the recent management change at Aimeike Technology Development Co., Ltd., with Li Dongmei appointed as the new Deputy General Manager and Board Secretary during a challenging period for the company [2] - Aimeike is facing significant challenges, with a reported revenue of 1.865 billion yuan for the first three quarters of 2025, representing a year-on-year decline of 21.49%, and a net profit of 1.093 billion yuan, down 31.05% year-on-year [3] - The decline in performance is attributed to intensified industry competition, particularly from Huaxi Biological's competing product "Runzhi·Gegge," which is affecting Aimeike's core product "Haitai" [3] Group 2 - Aimeike is embroiled in a dispute over the agency rights of its product AestheFill, which has escalated to a trademark infringement case involving a compensation claim of 1.6 billion yuan [4] - The appointment of a legal professional as a senior executive suggests that Aimeike aims to enhance its compliance, risk management, and arbitration dispute response capabilities [4] - Li Dongmei's nearly twenty years of legal experience is expected to provide professional support to Aimeike in navigating its current challenges [4]